

TruScreen

True potential

TruScreen (TRU) manufactures and distributes a unique testing device that detects cancerous and pre-cancerous cells in the cervix. The developing world, which has the highest incidence and mortality from cervical cancer, is the target market. TRU, which listed on the NZX in November 2014, has secured China Food and Drug Administration (CFDA) approval to market TruScreen in China, where there is no cervical cancer testing regime and a potential market of 388 million.

Business model

TRU manufactures, distributes and sells the TruScreen device for detecting cervical cancer. It manufactures in China and Australia. It is in the process of setting up sales and distribution networks in key target markets in the developing world. In April, it secured approval from the CFDA to market TruScreen in China. Since then, the company has commenced its first two major Chinese screening programmes, the first of which will run in co-operation with the China Doctors Association aimed at screening 100,000 women spread across every province of China, and the second run on behalf of China's largest oil company, Sinopec, with the aim of screening 130,000 women in the Shengli oil fields in north-east China.

In addition to China, TRU has cemented distribution agreements and commenced sales in South-East Asia, Central Asia, Latin America, the Middle East, Russia and Eastern Europe. It has also invested NZ\$1m in developing a smaller, wireless, more modern and future-proofed TruScreen device. This miniaturised and mobilised TruScreen is expected to be released to the market in late 2015.

Capital-raising

Since its last balance date, the company has raised an additional NZ\$5.1m through a NZ\$3.27m private placement in May and a NZ\$1.81m share purchase plan in June. These funds will enable the company to finance its current operations, set up manufacturing facilities for the upgraded miniaturised, wireless TruScreen device and continue its algorithm fefinement programme.

Valuation: No earnings forecasts available

There are no earnings forecasts available for TRU. The company reported revenues of NZ\$2.2m in the 12 months to March 2015, which was ahead of the NZ\$1.92m forecast in its prospectus.

Historical financials						
Year end	Revenue (NZ\$m)	PBT (NZ\$m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
03/14	0.0	(1.6)	(1.8)	0.0	N/A	N/A
03/15	2.2	(0.7)	(0.5)	0.0	N/A	N/A
Source: Cor	mpany reports					


Pharma & biotech

Price* NZ\$0.25 Market cap NZ\$39m

*As at 27 August 2015

4.0

Net cash (NZ\$m) as at 27 July 2015



Share details Code TRU Listing NZX Shares in issue 157.5m

Business description

TruScreen offers the latest technology in screening for the possibility of cervical cancer, which after breast cancer is the second most fatal cancer for women. The target market comprises one billion women in the developing world.

Bull

- Non-invasive test with a higher degree of accuracy than traditional Pap spear tests.
- Huge market potential in China.
- Real-time results.

Bear

- Targeting poorly funded developing countries.
- One-product company.
- Model relies on distribution partner in each jurisdiction.

Analysts

Dr Dennis Hulme +61 (2) 9258 1161 Finola Burke +61 (2) 9258 1161

healthcare@edisongroup.com



Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (www.fsa.gov.uk/register/firmBasicDetails.do/sid=181584). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Registered on the New Zealand Financial Services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

DISCLAMICEN
Copyright 2015 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers" exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding states escurities laws. As such, Edison ones not offer or provide personalised advice. We publish information about companies is which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) or brokers (for use in their roles as financial advisers or brokers) or brokers (for use in their roles as financial advisers or brokers) or brokers (for use in their roles as financial advisers or brokers) or brokers